|Anti-hCD20-hIgA1||Unit size||Cat. code||Docs||Qty||Price|
Monoclonal human IgA1 antibody against human CD20
Anti-hCD20-hIgA1 features the constant region of the human IgA1 isotype and the variable region of rituximab. Rituximab is a mouse/human chimeric monoclonal antibody that targets the CD20 antigen found on the surface of malignant and normal B lymphocytes. Binding of rituximab to CD20 results in cell destruction through different mechanisms including direct signaling of apoptosis, complement activation and cell-mediated cytotoxicity. Rituximab has been approved by the FDA for the treatment of various lymphoid malignancies, including B-cell non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukaemia. Anti-hCD20-hIgA1 was generated by recombinant DNA technology. It has been produced in CHO cells and purified by affinity chromatography with peptide M.
Clonality: Monoclonal antibody
Specificity: Targets cells expressing human CD20
Isotype: Human IgA1
100 µg purified anti-hCD20-hIgA1 antibody, provided azide-free and lyophilizedBack to the top